PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusDoes positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR.MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data.Economic image compression of output documentation of the most frequent examinations in nuclear medicine.Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis.Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma.Euthyroid goiter with and without nodules--diagnosis and treatment.Selective internal radiation therapy of hepatic tumors: procedural implications of a patent hepatic falciform arteryReduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization.Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRIAcquisition protocol considerations for combined PET/CT imaging.To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts?Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls.Unknown primary tumors: detection with dual-modality PET/CT--initial experience.Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging.Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer.False-positive FDG PET uptake--the role of PET/CT.Lymph node staging with dual-modality PET/CT: enhancing the diagnostic accuracy in oncology.Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen.PET versus PET/CT dual-modality imaging in evaluation of lung cancer.Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaCombined PET/MRI: a new dimension in whole-body oncology imaging?FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging.German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease.Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.Virtual 18F-FDG PET/CT bronchoscopy for lymph node staging in non-small-cell lung cancer patients: present and future applications.Hybrid PET/MR imaging of the heart: feasibility and initial results.Integrated FDG PET/MR Imaging for the Assessment of Myocardial Salvage in Reperfused Acute Myocardial Infarction.Scintigraphic peritoneography reveals a non-uniform (99m)Tc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model.In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany.Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.Reduced contribution of thermally-labile sugar lesions to DNA double-strand break formation after exposure to neutrons.Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer.
P50
Q26774920-88284D4E-3DAA-413D-8D74-AE755190F06FQ30581503-2777E4E3-646C-402A-BA92-CBEC92A11C10Q31032111-1CE628E5-2683-4351-B47E-E25FE38C5F45Q31147064-5859FE3B-EFDB-4E62-9E54-6C207B0C9CF1Q33292037-84DF4A1F-C4DD-4A7F-845E-EE2604F1CED3Q33790290-237A2C91-0DEE-4909-B561-5F43838C8CF8Q33919290-5710B2EA-290D-4FB1-867A-7FA5DA097B50Q34267582-A7D9A548-7776-4FE2-BF97-95E17DE59EDBQ34287193-E8BA3592-1183-46F2-826A-DC79BD7FA2F1Q34301746-55A04BDC-8234-40EA-A0E8-4A4B585CE619Q34339718-865DE942-9775-4E71-A9DC-2BA55BD4D681Q34637268-E6E96A84-457F-4246-B12C-B8637BCAE3A7Q35075280-7DEBC7E5-8C5F-4B5F-9F62-0103B8488037Q35208318-190ABF9E-ED57-485E-A094-279141BF6791Q35635208-B420F631-177A-45B7-9BB1-7A2864DF3EEDQ35635220-516A5BAA-A5E9-41D8-AE58-48ACA5B2112CQ35763616-554566FE-836E-4B0B-B37D-916C4F5AD304Q35840426-3DBA613A-213D-4146-AED8-526F9A414B40Q35963508-34A66DD8-9F7B-4567-84C9-D5698C62F41CQ35984456-6A5BDBC7-8E9D-44C9-AF17-192BF1BBA50FQ36166095-91E3871B-B178-4BD2-91A6-D2E80D9D176EQ36347469-C949A737-EC66-4F6F-97EB-F998666AE1C6Q36395812-B5636718-5131-404E-AF5E-E9BF4B33DBD5Q36699817-6B9AB5F7-9288-4B20-BBC4-81FBF4B15C78Q36913413-AD006953-168D-42E4-81D6-00E6F7FB53F7Q36969748-17875666-8116-437B-B402-3AFF6A5A5293Q37357107-52AF7068-1362-46A0-AAB4-2D44B5B4D1E3Q37469186-F05FCF8B-7BF4-4F95-A9D3-5681A0006609Q37508294-07325CB5-582F-4ADC-A139-81DF0A87B047Q37855681-FBB978EA-984C-4E56-A29F-3A9F30440F6BQ37864158-11EB4AE4-BA96-4083-9709-556D9E21CF83Q38018970-71E3184E-B668-4A6C-907B-5AC0563001E9Q38104827-E85AB8A6-452E-4FAE-8C33-8DAD9969A0B1Q38409102-AA0C55A3-0453-496D-8D54-6A1DF78BD94BQ38712794-9A64AC64-713B-4B25-86ED-A86983C5FAD9Q38984450-1F7460E9-1E31-4CAB-8DA3-040B28569ED7Q39116619-C73F1C34-2184-495F-A645-DA3A1B4C2823Q39253849-7CD14CD8-B468-45BE-BB9B-0C0E8086F3ABQ39255159-BB7C64EE-8ED5-46B9-AC3B-16A9D5B96D98Q39310595-213DDB53-2CBA-412F-98AA-F611B6AE8C25
P50
description
academisch docent
@nl
deutscher Nuklearmediziner
@de
name
Andreas Bockisch
@ast
Andreas Bockisch
@de
Andreas Bockisch
@en
Andreas Bockisch
@es
Andreas Bockisch
@nl
Andreas Bockisch
@sl
type
label
Andreas Bockisch
@ast
Andreas Bockisch
@de
Andreas Bockisch
@en
Andreas Bockisch
@es
Andreas Bockisch
@nl
Andreas Bockisch
@sl
prefLabel
Andreas Bockisch
@ast
Andreas Bockisch
@de
Andreas Bockisch
@en
Andreas Bockisch
@es
Andreas Bockisch
@nl
Andreas Bockisch
@sl
P214
P227
P166
P19
P21
P214
P227
119271332X
P31
P569
1950-01-10T00:00:00Z